The first tau SAA was described shortly after the α-synuclein protocol and aimed to discriminate the seeding profiles of postmortem brain and CSF samples from different tauopathies based on their ability to induce pathogenic conversion of the 3R tau K19CF (CF = cysteine free) substrate [75] (Table 1). Here, MAPT is linked to tauopathy.